

Paratus Clinical Research and Waitemata Clinical Research Announce Strategic Partnership

19th February 2026: Paratus Clinical Research and Waitemata Clinical Research have entered into a strategic partnership strengthening trans-Tasman clinical trial delivery across Australia and New Zealand.

The partnership combines Paratus' expertise and refined centralised functions with Waitemata Clinical Research's established, investigator-led site in Auckland, New Zealand. Together, the organisations will support sponsors seeking coordinated, high-quality trial execution across the ANZ region.

"This partnership represents an important step in Paratus' expansion into New Zealand," said Matt Clacy, Founder of Paratus Clinical Research. "Working with a trusted, high-quality site like Waitemata allows us to extend our model while maintaining the standards and consistency our sponsors value."

"We are excited to join Paratus Clinical Research's network of research sites, with the focus on high quality agile sites, to enhance further opportunities across the ANZ region" added Rachel Harris, founding Director of Waitemata Clinical Research.

Through the collaboration, sponsors can benefit from streamlined trial start-up, experienced investigator teams, and consistent oversight across both countries.

For feasibility discussions or to explore potential study opportunities within the Paratus-Waitemata partnership, sponsors, CROs and partners are encouraged to reach out to the Head of Strategic Partnerships, Heenal Patel, at Paratus Clinical.

Heenal.patel@paratusclinical.com

www.paratusclinical.com